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Abstract
Background: Late onset sepsis is a frequent complication of prematurity associated with increased mortality and
morbidity. The commensal bacteria of the gastrointestinal tract play a key role in the development of healthy
immune responses. Healthy term infants acquire these commensal organisms rapidly after birth. However,
colonisation in preterm infants is adversely affected by delivery mode, antibiotic treatment and the intensive care
environment. Altered microbiota composition may lead to increased colonisation with pathogenic bacteria, poor
immune development and susceptibility to sepsis in the preterm infant.
Probiotics are live microorganisms, which when administered in adequate amounts confer health benefits on the
host. Amongst numerous bacteriocidal and nutritional roles, they may also favourably modulate host immune
responses in local and remote tissues. Meta-analyses of probiotic supplementation in preterm infants report a
reduction in mortality and necrotising enterocolitis. Studies with sepsis as an outcome have reported mixed results
to date.
Allergic diseases are increasing in incidence in “westernised” countries. There is evidence that probiotics may
reduce the incidence of these diseases by altering the intestinal microbiota to influence immune function.
Methods/Design: This is a multi-centre, randomised, double blinded, placebo controlled trial investigating
supplementing preterm infants born at < 32 weeks’ gestation weighing < 1500 g, with a probiotic combination
(Bifidobacterium infantis, Streptococcus thermophilus and Bifidobacterium lactis). A total of 1,100 subjects are being
recruited in Australia and New Zealand. Infants commence the allocated intervention from soon after the start of
feeds until discharge home or term corrected age. The primary outcome is the incidence of at least one episode
of definite (blood culture positive) late onset sepsis before 40 weeks corrected age or discharge home. Secondary
outcomes include: Necrotising enterocolitis, mortality, antibiotic usage, time to establish full enteral feeds, duration
of hospital stay, growth measurements at 6 and 12 months’ corrected age and evidence of atopic conditions at 12
months’ corrected age.
Discussion: Results from previous studies on the use of probiotics to prevent diseases in preterm infants are
promising. However, a large clinical trial is required to address outstanding issues regarding safety and efficacy in
this vulnerable population. This study will address these important issues.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN012607000144415
The product “ABC Dophilus Probiotic Powder for Infants
®”, Solgar, USA has its 3 probiotics strains registered with
the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ - German Collection of Microorganisms
and Cell Cultures) as BB-12 15954, B-02 96579, Th-4 15957.
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The intestinal microbial community and probiotics
Late onset sepsis (> 48 hours after birth) is a frequent
complication in very preterm infants with high mortality
and morbidity. In 2003, the Australian and New Zealand
Neonatal Network (ANZNN) reported an incidence of
23% in very low birth weight infants (VLBW, less than
1500 grams) and 31% in extremely low birth weight
infants (ELBW, less than1000 grams), with 18% mortal-
ity [1]. Preterm infants are more susceptible to infection
as they have an immature immune system, which may
in part be due to the abnormal development of their
gastrointestinal microflora (microbiome). Molecular
microbiological studies estimate that the mature human
intestinal microbiome encompasses several hundred spe-
cies of microorganisms with concentrations approximat-
ing 10
12 viable microbes per gram of faecal content [2].
This microbiome performs numerous important func-
tions, including the digestion of macro and micronutri-
ents, regulation of host fat storage, the metabolism of
endogenous and exogenous compounds, immunoregula-
tion and limiting colonisation with pathogenic microbes
[3,4]. Disturbance of the gastrointestinal tract microbial
environment may predispose individuals to a variety of
diseases ranging from inflammatory bowel disease to
allergy and obesity [4-7].
Colonisation of the aseptic intestine occurs rapidly
after birth in healthy term infants. The intestinal micro-
bial community is acquired from the birth canal and
close parental contact after birth and is subsequently
modified by diet [8]. Preterm infants acquire colonizing
bacteria from the intensive care environment rather
than their mother’s vaginal canal, skin surface and milk
[9]. Caesarean section delivery may delay infants’ acqui-
sition of diverse commensal flora by up to a year com-
pared to vaginally delivered infants [10] and delivery by
caesarean section occurs more frequently in preterm
births (> 50% caesarean section rate for VLBW infants)
[11]. These infants often receive antibiotics perinatally
to prevent acute sepsis, and after birth for clinically sus-
pected or definite culture positive sepsis, which further
alters the composition of intestinal bacteria. Microbial
diversity in the intestine of preterm infants, as assessed
by culture-dependent methods, decreases with pro-
longed hospitalization [9,12-14]. Preterm infants also
have delayed colonization with healthy commensals,
such as Lactobacillus and Bifidobacterium species,
which may lead to altered function of the gut microbial
community, particularly the immune functions [9,15-19].
Probiotics are defined as live microorganisms, which
when administered in adequate amounts may confer
health benefits on people with specific illnesses [20].
Postulated mechanisms by which they may protect the
host from gastrointestinal and urinary infections include:
increasing resistance of the mucosal barrier to migration
of bacteria and their toxins by strengthening intestinal
cell junctions, modification of host response to micro-
bial products, augmentation of immunoglobulin A
mucosal responses, enhancement of enteral nutrition to
inhibit the growth of pathogens; production of bacterio-
cins (small proteins which kill bacteria); and competitive
exclusion of potential pathogens [21-25]. It has been
hypothesized that very preterm infants, who have less
microbial diversity in their GIT, may benefit from colo-
nization with exogenously administered probiotics.
Depending on the strain(s) administered, these probio-
tics could potentially induce a similar microbial commu-
nity to that of the term infant or adult gastrointestinal
microbiome [25]. The mechanisms by which probiotics
may prevent the development of allergic disease are sug-
gested to include all of the probiotic effects listed above
as well as the induction of immune regulatory pathways
Evidence from clinical trials of probiotics for prevention
of sepsis and NEC in preterm infants
Several meta-analyses and systematic reviews of rando-
mised controlled trials (RCTs) of probiotic use in pre-
term infants have been published in recent years
[26-29]. The most promising results relate to supple-
mentation with probiotics to prevent necrotising entero-
colitis (NEC) and to reduce all-cause mortality.
Necrotising enterocolitis (NEC) is a relatively rare
complication of prematurity. The incidence is inversely
related to gestational age at birth. Overall, 88% of all
reported cases in Australia in 2005 occurred in infants
born before 32 weeks of completed gestation [1]. It is
the most serious gastrointestinal problem of preterm
infants and can rapidly progress from gastrointestinal
dysfunction to bowel perforation and death in those
most severely affected. Worldwide, the incidence is
reported to be 1-3/1,000 live births and NEC affects
approximately 10% of preterm infants born weighing
less than1,500 grams [30]. Of those seriously affected,
about half will require surgery to repair or excise dis-
eased gastrointestinal tract and 25% will die. Long-
term morbidity in survivors includes intestinal stric-
tures, poor nutritional status and neurodevelopmental
impairment [31-33]. No specific treatment exists for
NEC; generally enteral feeds are ceased, with the
administration of intravenous nutrition and broad
spectrum antibiotics.
Cultivation and molecular-based studies have demon-
strated quantitative and qualitative changes in faecal
flora in the NEC prodrome; however, no single causative
organism has been identified. Suggested pathogens have
included bacteria (E. coli, Clostridia perfringens,
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ona-, noro-, etc.) and fungi (Aspergillus and Mucor spp.)
[12,13,16,34-36]. NEC affected infants have also been
shown to have lower species diversity in their gastroin-
testinal tract and this may limit the ability of their
microbiome to perform its important immunoprotective
functions.
The most recently published systematic review in
2,842 preterm infants concluded that enteral probiotic
supplementation significantly reduces the incidence of
severe NEC (Bell stage II or more) (typical RR 0.35, 95%
CI 0.24 to 0.52) and mortality (typical RR 0.40, 95% CI
0.27 to 0.60) [29,37]. Other studies investigating probio-
tic use in very preterm infants have also reported
favourable effects on the incidence of NEC, time to full
enteral feeds, weight gain, colonisation rates and
immune responses in the probiotic versus placebo group
[38-43].
These studies support the hypothesis that augmenta-
tion of the intestinal microbiome of premature infants
with exogenous probiotics (healthy organisms) may
favourably alter the microflora resulting in an improve-
ment in clinical outcomes. While these results are very
promising, debate continues regarding the routine use
of probiotics in preterm infants [44-46]. Many trials in
these meta-analyses do not include the most vulnerable
preterm infants, those born weighing less than 1,000
grams and before 28 weeks’ gestation. In addition, there
is a lack of data regarding the optimal strain(s), dose,
time to start and duration of probiotic therapy, as well
as the taxonomy and quality of currently available pro-
biotics formulations and products. Further large clinical
trials using products registered with microbial culture
banks (for quality assurance) are required to resolve
these issues and to support the development of probio-
tic products of pharmaceutical quality. Probiotic supple-
mentation has not yet been evaluated in a population of
Australian very preterm infants.
Results of studies investigating the use of probiotics to
reduce the incidence or severity of sepsis have been
equivocal. The Cochrane Database systematic review
found no evidence of significant reduction of nosoco-
mial sepsis (typical RR 0.90, 95% CI 0.76 to 1.07) [29],
although some of the earlier individual RCTs demon-
strated a difference in sepsis rates between probiotic
and placebo groups [47,48]. The lack of effect reported
in the Cochrane review may be due to the heterogeneity
of the RCTs included in the review with regard to the
variation in probiotic strains studied, the method of
administration (dosage, frequency, duration, etc.) or dif-
ferences in local nursery guidelines for the diagnosis
and treatment of sepsis. Also, the sub-group of ELBW
preterm infants who are most susceptible to late onset
sepsis is under-represented as only small numbers of
them were recruited to published trials.
These issues are being addressed by this large (1,100
participants), multi-centre, randomised, double-blinded,
placebo controlled trial, which has adequate power to
demonstrate clinically significant effects of the chosen
probiotic mixture on the rate of late-onset sepsis in
VLBW infants but not on NEC. It is also sufficiently
powered to demonstrate any significant adverse effects
in infants below 1000 g birth weight and less than 28
weeks’ gestation.
Evidence from clinical trials of probiotics for the
prevention of allergic disease
An epidemic rise in allergic disease in “westernised”
countries, especially food allergy and asthma, has
occurred in parallel with many lifestyle changes [49].
Studies have linked alterations in the intestinal micro-
flora in infants with the later development of allergic
disease [50-52]. These abnormalities particularly
involved Bifidobacterium species [53-57] and microbial
diversity [12]. Probiotics are capable of inducing an
intestinal microflora composition similar to that of a
healthy breastfed term infant [58]. Therefore, they may
have the potential to reduce allergic diseases by “nor-
malising” the gastrointestinal tract microflora. Probiotics
can also modulate immune function by altering dendri-
tic cell [59], regulatory T cell [60,61], and T helper cell
responses [62]. A Cochrane Library meta-analysis of
probiotic supplementation for the prevention of allergic
d i s e a s ei nt e r mi n f a n t sf o u n das i g n i f i c a n tr e d u c t i o ni n
eczema in infants who received probiotics compared
with those that did not [typical RR 0.82, 95% CI 0.70,
0.95] and further trials were recommended to determine
the reproducibility of the results [63].
A more recent review and meta-analysis reported that
a protective effect against allergic disease was only
observed if probiotic supplementation were initiated in
the prenatal period and continued postnatally, but not if
probiotic supplementation were commenced postnatally
[64]. However, there were only 4 small studies that
administered probiotics postnatally, with 1 of these 4
studies reporting a beneficial effect from postnatal sup-
plementation [65-68]. Therefore, further studies are
required to determine if postnatal administration of pro-
biotics might be beneficial for prevention of allergic
disease.
Aim of this study
The primary aim of this study is to determine the effect
of probiotic organisms, ingested daily by VLBW preterm
infants (below 1500 g and less than 32 weeks’ gestation
at birth) from shortly after birth, on the incidence of
Garland et al. BMC Infectious Diseases 2011, 11:210
http://www.biomedcentral.com/1471-2334/11/210
Page 3 of 10definite late onset sepsis, diagnosed after 48 hours of age
and before term or discharge home, whichever occurs
sooner. A secondary aim is to investigate the effects of
probiotics on allergic diseases in this population.
Methods/Design
Trial Design
￿ Type of trial
This is a multi-centre, prospective, randomised, double
blind, placebo controlled trial investigating the treat-
ment of very preterm infants with a probiotic combina-
tion comprising Bifidobacterium infantis, Streptococcus
thermophilus and Bifidobacterium lactis ("ABC Dophilus
Probiotic Powder for Infants
®”, Solgar, USA). The study
powder contains 1 × 10
9 total organisms per 1.5 gm.
￿ Subjects and centres
A total of 1,100 subjects are being recruited and rando-
mised from 12 perinatal centres around Australia and
New Zealand (The Royal Women’s Hospital, The Mercy
Hospital for Women and Monash Medical Centre in
Victoria; Royal North Shore Hospital, The Royal Prince
Alfred Hospital, The Royal Hospital for Women, Liver-
pool Women’s Hospital, Westmead Hospital and John
Hunter Hospital in New South Wales; The Royal Hobart
Hospital in Tasmania; and Auckland City Hospital and
Christchurch Women’s Hospital in New Zealand). Vic-
torian recruits are offered the opportunity to participate
in allergy assessments at 12 months’ corrected age via
maternal telephone questionnaire or assessment at The
Royal Children’s Hospital, Melbourne.
Parents are approached to consent to their baby’sp a r -
ticipation in the trial if they satisfy the inclusion and
exclusion criteria (see below). Parents are provided with
their own copy of the Patient Information and Consent
Form and written consent is obtained from them.
Infants enrolled from the Victorian centres are offered
the opportunity to participate in allergy assessments at
12 months’ corrected age, with consent for this being
sought during the primary hospital admission.
￿ Duration of participation
Infants are given the probiotic or placebo from soon
after the start of milk feeds until discharge home or
term corrected age, whichever comes first. Victorian
infants are followed until 12 months’ corrected age.
￿ Timeline
Start of trial: October 2007
Recruitment period: estimated to be completed by
March 2012
Time frame for statistical analysis: 6 months
Time frame for manuscript preparation: 6 months
The duration of the study is expected to be about 5
years from the beginning of subject recruitment, until
the last data collection point.
￿ Study population
Inclusion criteria a. Preterm infants both below 1500 g
and less than 32 weeks’ gestational age at birth
b. Enrolled within 72 hours of birth
Exclusion criteria a. Major or suspected major congeni-
tal anomalies
b. Considered likely to die within 72 hours of birth
c. Parents from whom informed consent cannot be
obtained. Babies of mothers who are already taking sup-
plemental probiotics by capsule (not yoghurt, etc.)
Outcomes
￿ T h ep r i m a r yo u t c o m ei st h ei n c i d e n c eo fa t
least one episode of definite (blood culture posi-
tive) late onset sepsis before 40 weeks corrected
age or discharge home, whichever occurs sooner.
￿ The secondary outcomes are:
- incidence of clinically-suspected sepsis (blood cul-
ture negative sepsis)
- NEC, graded by modified Bell’s criteria [37]
- mortality
- duration of the primary hospital admission
- number of courses of antibiotics
- number of days until full enteral feeds established
(120 ml/kg/day or more for 3 consecutive days)
- In a subgroup of Victorian subjects at 12 months’
corrected age:
(i) growth, including weight, length and head
circumference
(ii) infections, hospital admissions and antibiotic
courses
(iii) cumulative incidence of allergic disease, includ-
ing atopic eczema, food allergy, and asthma/wheeze
at 12 months as assessed by questionnaire [69,70]
(iv) immunological parameters including serum
immunoglobulins, number of T- regulatory cells
(Tregs) and levels of T- regulatory cytokines (Inter-
leukin-10 and Transforming Growth Factor-b
(TGFb)) produced by mononuclear cells in-vitro
[70].
(v) allergic sensitisation at 12 months - skin prick
testing to a panel of common allergens (Egg white,
milk, peanut, cat hair, grass pollen and house dust
mite)
Intervention and quality control
￿ Product description/Composition
The probiotic is the “ABC Dophilus Probiotic Powder
for Infants
®”, Solgar, USA, containing 1 × 10
9 of total
organisms/daily 1.5 g dose in a maltodextrin powder.
This consists of Bifidobacterium lactis, Streptococcus
thermophilus and Bifidobacterium infantis. The placebo
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dextrin. The maltodextrin powder contains 4 kcal/gram
and is dairy free, gluten free and suitable for vegans.
The daily dose is 1.5 g of study powder, irrespective of
infant’s weight or postnatal age.
￿ Confirmation of quality and safety of the probiotic
“ABC Dophilus Probiotic Powder for Infants
®” is
imported from Solgar, USA. This research team holds
the import license obtained from the Australian Thera-
peutic Goods Administration Clinical Trial Notification
(CTN) Scheme. The Solgar Company certify the quality
of product through their established company protocols
and ensure the correct transport of product to the phar-
macy at The Royal Women’s Hospital, Melbourne.
Taxonomy and quality of the probiotic organisms was
confirmed by Dr. Barry Kiely of The Alimentary Phar-
mabiotic Institute, Cork, Ireland. Each batch of study
and placebo powder is tested for the presence of patho-
gens using standard microbiological techniques and for
the presence and quantitation of the probiotic organisms
using real-time polymerase chain reaction techniques.
This testing is undertaken at the microbiology labora-
tories of The Royal Children’sa n dW o m e n ’s Hospitals,
Melbourne.
￿ Packaging and labeling with blinding
The probiotic and placebo powders are identically pack-
aged by The Royal Women’s Hospital Pharmacy Depart-
ment, which holds the randomisation code. Each jar of
study powder is identified with this unique code as well
as the infant’s medical record number following
randomisation.
￿ Product handling
All study powder is supplied by Solgar
®,U S A .I ti sd i s -
tributed by The Royal Women’s Hospital Pharmacy
Department to the individual study sites, where it is
stored in a refrigerated dry environment at 4°C tempera-
ture. The investigators agree not to supply the study
powder to any person except the infants participating in
this trial.
Management of subjects
￿ Route of administration
The study intervention/placebo is given orally or via
gastric tube once daily, unless the feed volume is less
than 3 mL when one level ProPrems trial measuring
spoon of powder is administered in 1.5 mL feed twice
daily. Freshly expressed mother’s breast milk is the feed
of choice followed by frozen breast milk, if fresh is not
available. Banked breast milk is used when mother’s
milk is not available in centres with established proto-
cols that use breast milk banking. Formula is used only
when there is insufficient breast milk or if the mother
chooses not to provide breast milk. Tube feeding is
commenced as soon as possible in small and increasing
amounts according to local protocols and the discretion
of the treating neonatologist. Intravenous fluids and
nutrition are used until approximately 120 ml/kg of
milk is tolerated per 24 hour period. Feeding protocols
aim to maximise the use of enteral feeding and mini-
mise the use of central venous lines.
￿ Confirmation of probiotic colonisation
In Victoria, infants’ stool carriage of probiotic species is
documented to test for colonisation prior to the first
dose of probiotic or placebo and then at 1, 4, and 8
weeks from treatment, and at 6 and 12 months’ cor-
rected age. Stool swabs are rotated in 200 μLo fp h o s -
phate buffered saline (PBS) and DNA extracted as per
the methods described by Furet, et al and Matsuki, et al.
[71,72]. Extracted DNA is test e db yq u a n t i t a t i v er e a l -
time PCR for Bifidobacterium infantis, Bifidobacterium
lactis and Streptococcus thermophilus using primers and
probes directed at a 16S rRNA and 16S-23S integrated
spacer gene respectively [73,74]. These methods are
more sensitive than conventional culture techniques
with detection limits of approximately 1 colony-forming
unit/ml. This testing is undertaken at the Women’s
Centre for Infectious Diseases Molecular Microbiology
Laboratory, The Royal Women’s Hospital, Melbourne.
￿ Compliance
The probiotic study powder is administered, as ordered
on the medication chart, until the baby reaches term
corrected age or is discharged home from hospital,
whichever comes first. Administration is monitored by
the research team at each study centre.
￿ Allergy assessment at 12 months’ corrected age
Infants enrolled at the 3 Victorian sites are eligible for
the 12 month corrected age allergy assessment. This is
coordinated by a study nurse and involves either a
maternal telephone questionnaire or an assessment at
The Royal Children’s Hospital (RCH), Melbourne. Par-
ents who consent to their infants’ being assessed at 12
months’ corrected age are asked to keep a written
record of any infections, hospital admissions or allergic
symptoms experienced by their child during this time
period.
There are several components to the allergy
assessment:
(i) A parental questionnaire is used to assess the inci-
dence and severity of atopic eczema, food allergies and
wheeze from term until 12 months’ corrected age. This
is a validated questionnaire which has been adapted
from the Probiotic Eczema Prevention Study (Principal
Investigator M. Tang) [70].
(ii) Where permission is given on the day, a blood
sample (1 - 2 ml) is collected following the application
of a topical anaesthetic (Emla 5%) to minimize distress
to the child. Serum and peripheral blood mononuclear
cells are isolated for future batched analysis of serum
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production of IL-10 and TGFb levels. These studies will
be performed at the Murdoch Children’s Research Insti-
tute (M Tang, Allergy and Immune Disorders Research
Group).
(iii) Skin-prick testing (SPT) is offered to determine
sensitization to common allergens (Egg white, milk, pea-
nut, cat hair, pollen, house dust mite (DerP1), 10 mg
Histamine and a negative control). Participants with
SPT responses ≥3 mm above the negative control are
referred to the Paediatric Allergy Service for further
assessment and management, including confirmatory
oral food challenge if required.
￿ Study withdrawal
In the case of early withdrawal from the study, a
research nurse records any reason given for withdrawal
and attempts to collect as much data as possible on the
Case Report Form. If Victorian parents refuse to con-
tinue the study treatment, they are asked if they are
willing to participate in the 12 month follow-up ques-
tionnaires. If parents do not agree, they are not con-
tacted any more. If participant withdrawal amounts to >
1% ie.11 subjects, 1% additional subjects will be
recruited to compensate for missing data. Minimal data
is collected on infants whose parents decline to be
involved in the study, to ensure that participants are
representative of the eligible population to ensure that
the denominator can be estimated.
Conduct of the trial
￿ Randomisation
This is achieved using variable block design constructed
by the Clinical Epidemiology and Biostatistics Unit
(CEBU) at the Murdoch Children’s Research Institute,
who are independent of the study investigators. Each
block contains equal numbers of placebo and active
allocation. Randomisation is stratified by unit. Each of
the participating neonatal units is able to access the
next sequentially numbered probiotic or placebo imme-
diately after randomisation. Records are kept and
audited to check that sequential randomisation is used
to assign infants to either study group. All doctors,
nurses, research assistants, laboratory staff and parents
are blind to the randomised allocation. The key is held
by the Chief Pharmacist at The Royal Women’s Hospital
and the trial statistician, both of whom are independent
of the investigators and not involved in outcome
assessment.
￿ Breaking of the code
All attempts to avoid breaking the code will be made for
t h ed u r a t i o no ft h es t u d y .T h ec o d eb r e a km a yb eu s e d
by one of the 5 Chief Investigators (CI) directly in true
emergencies after consultation with at least one other
CI. In such cases the rationale must be documented,
with immediate notification of the Project Leader. The
code break will also be reported in the participant speci-
fic case report form (CRF) and events leading to the
emergency breaking will be recorded in the serious
adverse event (SAE) report form. SAEs will also be noti-
fied to all ethics committees and the Therapeutic Goods
Administration [75].
￿ Data management
Hard copies of the study data are stored in locked filling
cabinets at each study centre. Electronic data will be
stored in the Department of Newborn Research at the
Royal Women’s Hospital, Melbourne on secure pass-
word protected computers for 25 years. Every effort will
be made to obtain the highest volume of follow-up data.
Statistical Aspects and Consideration
￿ Sample size calculation
Statistical advice has been provided on all aspects of
s t u d yd e s i g n ,s a m p l es i z ea n da n a l y s e sb yC E B U ,w h o
will assist in analysis at trial completion.
To reduce the incidence of culture proven sepsis from
23% to 16% (a 33% reduction) with a power of 0.8, a of
0.05, and a 2-tailed test, the estimated sample size is
530 per group. The trial will therefore recruit 1,100
infants over 5 years, based on our experience that 50%
of parents consent to participation in this preterm
population.
￿ Statistical Analysis
Intention to treat analysis: Data from all randomised
participants will be considered in the intention-to-treat
model (for the primary outcome).
Per protocol analysis: Per protocol evaluation will
exclude data from participants who did not receive the
intervention.
Interim analyses: An independent data monitoring
committee (DMC) consisting of an independent paedia-
trician with expertise in neonatal sepsis, an epidemiolo-
gist, and two neonatologists with clinical trials
experience has been appointed. Full interim analyses of
all outcomes are being undertaken as data is received
when 100, 400 and 700 recruits have completed the
study. An additional interim analysis of mortality
occurred when 200 participants reached term corrected
age. Any adverse events, which on further assessment
appear likely to be due to the probiotics, are reported to
the clinical trial steering committee, the local hospital
research committees at participating centres and where
appropriate, the Therapeutic Goods Administration.
Legal and Ethical Prerequisites
￿ Legal requirements
This study is carried out according to the National
Statement on Ethical Conduct in Research Involving
Humans (March 2007) produced by the National Health
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mation has been developed to protect the interests of
people who participate in research studies.
￿ Ethical aspects
Protection of the subject’s confidentiality Confidential-
ity of all study participants is maintained; codes for sub-
ject identification are utilised. Identifying or confidential
data is kept in locked cabinets or password protected
computer databases, accessible only by named
investigators.
Informed consent When the investigator has deter-
mined that the potential participant is eligible for the
study, the study is described and explained verbally to
his/her parent/legal representative. The investigator fully
answers all questions. A copy of the information sheet is
given to his/her parent/legal representative.
Written, informed consent is obtained from each par-
ticipant’s parent/legal representa t i v eb yt h ei n v e s t i g a t o r
prior to enrolment in the study. The consent form is
signed and dated by the parent or the infant’s legal
representative and the investigator. The consent form is
completed in two copies: the first copy is given to the
parents or guardians and the second is stored in the
participants’ medical record. No participant receives
treatment before completion of the written informed
consent.
Ethics Committee Approval The study protocol has
been approved by the institutional Human Research and
Ethics Committee (HREC) of each participating centre.
The initial approval was granted by The Royal Women’s
Hospital HREC. The RWH project approval number is
06/31. The local ethics committee is notified of all sub-
sequent additions or changes in the study protocol. Reg-
ular notification of the ethics committees is also
required for any serious adverse events during the clini-
cal trial.
Declaration of Helsinki This trial is being conducted
according to the principles and rules laid down in the
Declaration of Helsinki and its subsequent amendments.
￿ Termination of study
Should it prove necessary to discontinue the study per-
manently prior to completion, the chief investigators:
Prof Suzanne Garland, Dr Tobin, Dr Jacobs, Dr Pirotta,
and A/Professor Tabrizi will reach a consensus decision
that this is required and sign a joint document to notify
the investigators and additional contacts, including the
HRECs, of the rationale. All study relevant documents
will then be returned to The Royal Women’sH o s p i t a l ,
VIC, and the study product will be destroyed or
returned.
Discussion
Late onset sepsis is associated with high mortality and
morbidity in preterm infants. Abnormalities in their
intestinal microbiota development, which has important
immune functions, may explain their increased suscept-
ibility to infection. Disturbance of the gastrointestinal
tract microbial environment predisposes adults and chil-
dren to disease, including inflammatory bowel disease,
allergy and obesity [4-7]. It has been hypothesized that
very preterm infants, who have less microbial diversity
in their GIT, may benefit from colonisation with exo-
genously administered probiotics.
Probiotics are defined as live microorganisms, which
when administered in adequate amounts may confer
health benefits on the host [20]. The most recently pub-
lished systematic review of probiotic supplementation in
preterm infants concluded that enteral probiotics signifi-
cantly reduces the incidence of severe Necrotising
Enterocolitis and mortality [29,37]. Other favourable
effects reported include reduced time to full enteral
feeds, improved weight gain, colonisation rates and
immune responses in the probiotic versus placebo group
[38-43].
The effect of probiotics on the incidence or severity of
sepsis has been equivocal. This may be due to the het-
erogeneity of the RCTs included in the most recent
Cochrane review with regard to the variation in probio-
tic strains studied, the method of administration
(dosage, frequency, duration, etc.) or differences in local
nursery guidelines for the diagnosis and treatment of
sepsis. Also, the sub-group of ELBW preterm infants
who are most susceptible to late onset sepsis is under-
represented in the review.
Whilst the above findings appear promising, debate
continues regarding the routine use of probiotics in this
vulnerable population [44-46]. Further large clinical
trials using products registered with microbial culture
banks (for quality assurance) are required to support the
development of probiotic products of pharmaceutical
quality. This large multi-centre, randomised, double
blinded, placebo controlled trial has adequate power to
demonstrate clinically significant effects of the chosen
probiotic mixture on the rate of late-onset sepsis in
VLBW infants. It is also sufficiently powered to demon-
strate any significant adverse effects in infants below
1000 g birth weight and less than 28 weeks’ gestation.
More than 900 infants have been enrolled to date, there-
fore, we are on course to reach our target recruitment
number of 1,100 participants and anticipate that results
will be available in early 2012.
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